“Lenvatinib Is More Effective & Safer Than Sorafenib in the Treatment of Renal Cell Carcinoma - A Single-Center Retrospective Analysis of 70 Cases”. 2024. Journal of Carcinogenesis 23 (1): 624-28. https://doi.org/10.64149/J.Carcinog.23.1.624-628.